Page 75 - Read Online

Page 12 of 13 Zhang et al. Cancer Drug Resist 2024;7:30 https://dx.doi.org/10.20517/cdr.2024.62

37. Li M, Zou X, Xia T, et al. A five-miRNA panel in plasma was identified for breast cancer diagnosis. Cancer Med 2019;8:7006-17.
DOI PubMed PMC
38. Wang YW, Xu Y, Wang YY, et al. Elevated circRNAs circ_0000745, circ_0001531 and circ_0001640 in human whole blood:
potential novel diagnostic biomarkers for breast cancer. Exp Mol Pathol 2021;121:104661. DOI PubMed
39. Kurozumi S, Seki N, Narusawa E, et al. Identification of microRNAs associated with histological grade in early-stage invasive breast
cancer. Int J Mol Sci 2023;25:35. DOI PubMed PMC
40. Verma VK, Beevi SS, Nair RA, et al. MicroRNA signatures differentiate types, grades, and stages of breast invasive ductal carcinoma
(IDC): miRNA-target interacting signaling pathways. Cell Commun Signal 2024;22:100. DOI PubMed PMC
41. Li X, Zou W, Wang Y, et al. Plasma-based microRNA signatures in early diagnosis of breast cancer. Mol Genet Genomic Med
2020;8:e1092. DOI PubMed PMC
42. Jiang W, Yu Y, Ou J, Li Y, Zhu N. Exosomal circRNA RHOT1 promotes breast cancer progression by targeting miR-204-5p/ PRMT5
axis. Cancer Cell Int 2023;23:260. DOI PubMed PMC
43. Turco C, Esposito G, Iaiza A, et al. MALAT1-dependent hsa_circ_0076611 regulates translation rate in triple-negative breast cancer.
Commun Biol 2022;5:598. DOI PubMed PMC
44. Yang SJ, Wang DD, Zhong SL, et al. Tumor-derived exosomal circPSMA1 facilitates the tumorigenesis, metastasis, and migration in
triple-negative breast cancer (TNBC) through miR-637/Akt1/β-catenin (cyclin D1) axis. Cell Death Dis 2021;12:420. DOI PubMed
PMC
45. Wang B, Mao JH, Wang BY, et al. Exosomal miR-1910-3p promotes proliferation, metastasis, and autophagy of breast cancer cells by
targeting MTMR3 and activating the NF-κB signaling pathway. Cancer Lett 2020;489:87-99. DOI PubMed
46. Shiino S, Matsuzaki J, Shimomura A, et al. Serum miRNA-based prediction of axillary lymph node metastasis in breast cancer. Clin
Cancer Res 2019;25:1817-27. DOI PubMed
47. Wang H, Tan Z, Hu H, et al. microRNA-21 promotes breast cancer proliferation and metastasis by targeting LZTFL1. BMC Cancer
2019;19:738. DOI PubMed PMC
48. Yuan X, Qian N, Ling S, et al. Breast cancer exosomes contribute to pre-metastatic niche formation and promote bone metastasis of
tumor cells. Theranostics 2021;11:1429-45. DOI PubMed PMC
49. Alunni-Fabbroni M, Majunke L, Trapp EK, et al; SUCCESS Study Group. Whole blood microRNAs as potential biomarkers in post-
operative early breast cancer patients. BMC Cancer 2018;18:141. DOI PubMed PMC
50. Bao S, Hu T, Liu J, et al. Genomic instability-derived plasma extracellular vesicle-microRNA signature as a minimally invasive
predictor of risk and unfavorable prognosis in breast cancer. J Nanobiotechnology 2021;19:22. DOI PubMed PMC
51. Raghu A, Magendhra Rao AKD, Rajkumar T, Mani S. Prognostic implications of microRNA-155, -133a, -21 and -205 in breast cancer
patients’ plasma. Microrna 2021;10:206-18. DOI PubMed
52. Liu B, Pan J, Fu C. Correlation of microRNA-367 in the clinicopathologic features and prognosis of breast cancer patients. Medicine
2021;100:e26103. DOI PubMed PMC
53. Záveský L, Jandáková E, Weinberger V, et al. Small non-coding RNA profiling in breast cancer: plasma U6 snRNA, miR-451a and
miR-548b-5p as novel diagnostic and prognostic biomarkers. Mol Biol Rep 2022;49:1955-71. DOI PubMed
54. Satomi-Tsushita N, Shimomura A, Matsuzaki J, et al. Serum microRNA-based prediction of responsiveness to eribulin in metastatic
breast cancer. PLoS One 2019;14:e0222024. DOI PubMed PMC
55. Wang J, Wang Q, Guan Y, et al. Breast cancer cell-derived microRNA-155 suppresses tumor progression via enhancing immune cell
recruitment and antitumor function. J Clin Invest 2022;132:e157248. DOI PubMed PMC
56. Zhong W, Bao L, Yuan Y, Meng Y. CircRASSF2 acts as a prognostic factor and promotes breast cancer progression by modulating
miR-1205/HOXA1 axis. Bioengineered 2021;12:3014-28. DOI PubMed PMC
57. Liang G, Ling Y, Mehrpour M, et al. Autophagy-associated circRNA circCDYL augments autophagy and promotes breast cancer
progression. Mol Cancer 2020;19:65. DOI PubMed PMC
58. Garrido-Cano I, Pattanayak B, Adam-Artigues A, et al. MicroRNAs as a clue to overcome breast cancer treatment resistance. Cancer
Metastasis Rev 2022;41:77-105. DOI PubMed PMC
59. Bao C, Chen J, Chen D, et al. MiR-93 suppresses tumorigenesis and enhances chemosensitivity of breast cancer via dual targeting
E2F1 and CCND1. Cell Death Dis 2020;11:618. DOI PubMed PMC
60. Cataldo A, Cheung DG, Balsari A, et al. miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the
cellular DNA damage response. Oncotarget 2016;7:786-97. DOI PubMed PMC
61. Papaspyropoulos A, Hazapis O, Lagopati N, et al. The role of circular RNAs in DNA damage response and repair. Cancers
2021;13:5352. DOI PubMed PMC
62. Lu X, Liu R, Wang M, et al. MicroRNA-140 impedes DNA repair by targeting FEN1 and enhances chemotherapeutic response in
breast cancer. Oncogene 2020;39:234-47. DOI
63. Lin S, Yu L, Song X, et al. Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-
mediated DNA damage response. Cell Death Dis 2019;10:666. DOI PubMed PMC
64. Strasser A, Vaux DL. Cell death in the origin and treatment of cancer. Mol Cell 2020;78:1045-54. DOI PubMed
65. Tao L, Wu YQ, Zhang SP. MiR-21-5p enhances the progression and paclitaxel resistance in drug-resistant breast cancer cell lines by
targeting PDCD4. Neoplasma 2019;66:746-55. DOI PubMed
66. Duan WJ, Bi PD, Ma Y, Liu NQ, Zhen X. MiR-512-3p regulates malignant tumor behavior and multi-drug resistance in breast cancer